Photo by nci from unsplash
In this issue of Cancer Cell, Gong et al. have analyzed the sensitivity of 560 cell lines to the selective CDK4/6 inhibitor abemaciclib and have defined cancers with specific genomic "D-cyclin… Click to show full abstract
In this issue of Cancer Cell, Gong et al. have analyzed the sensitivity of 560 cell lines to the selective CDK4/6 inhibitor abemaciclib and have defined cancers with specific genomic "D-cyclin activating features (DCAF)" as particularly vulnerable. These findings will facilitate patient selection as development of this drug class continues.
Keywords:
predicting response;
cdk4;
genomic biomarkers;
response selective;
biomarkers predicting;
selective cdk4
Journal Title: Cancer cell
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Cancer cell
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!